[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584820":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":59,"collaborators":7,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":7,"enrollmentInfo":71,"targetDuration":74,"studyType":75,"phases":7,"briefSummary":76,"conditions":77,"keywords":7,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Amplified Sciences Inc","INDUSTRY",null,[9,29,44],{"facility":10,"status":11,"city":12,"state":13,"zip":14,"country":15,"countryCode":16,"cosmosGeoPoint":17,"geoPoint":22,"contacts":23},"Indiana University","RECRUITING","Indianapolis","Indiana","46202","United States","US",{"type":18,"coordinates":19},"Point",[20,21],-86.15804,39.76838,{"lat":21,"lon":20},[24],{"name":25,"role":26,"phone":27,"phoneExt":7,"email":28},"Mohammad Al-Haddad, MD","CONTACT","317-278-9242","petermaj@iu.edu",{"facility":30,"status":11,"city":31,"state":32,"zip":33,"country":15,"countryCode":16,"cosmosGeoPoint":34,"geoPoint":38,"contacts":39},"Beth Israel Deaconess Medical Center","Boston","Massachusetts","02215",{"type":18,"coordinates":35},[36,37],-71.05977,42.35843,{"lat":37,"lon":36},[40],{"name":41,"role":26,"phone":42,"phoneExt":7,"email":43},"Mandeep Sawhney, MD","617-667-4046","rdastjer@bidmc.harvard.edu",{"facility":45,"status":11,"city":46,"state":47,"zip":48,"country":15,"countryCode":16,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"Rutgers Health","New Brunswick","New Jersey","08901",{"type":18,"coordinates":50},[51,52],-74.45182,40.48622,{"lat":52,"lon":51},[55],{"name":56,"role":26,"phone":57,"phoneExt":7,"email":58},"Arvind Trindade, MD","732-235-7784","molly.stewart1@rutgers.edu",{"type":60,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100584820","a-study-for-the-pancystpro-assay-in-the-management-of-pancreatic-cystic-lesions-100584820",false,"NCT06894329","A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions","Clinical Utility Study to Determine Impact of PanCystPro Assay on Physician Decision-making in the Management of Pancreatic Cystic Lesions","PanAMP","Inclusion Criteria:\n\n* Patients 18 years of age or older\n* Cross sectional imaging studies demonstrating a pancreatic cyst at least 12 mm in size where fluid sampling can aid in patient's management\n* Written informed consent.\n* The patient will be undergoing EUS with anticipated FNA extraction as part of standard patient care.\n\nExclusion Criteria:\n\n* Patients diagnosed with pancreatic cancer.\n* Pregnant or lactating females.\n* Patients with contraindications to moderate or deep procedural sedation (necessary for the conduct of the endoscopic ultrasound) like major cardiorespiratory illness.\n* Patients with contraindications to FNA of a pancreatic cyst like being on blood thinners.","ALL","18 Years",{"count":72,"type":73},50,"ESTIMATED","12 Months","OBSERVATIONAL","The purpose of this research is to learn if the PanCystPro assay can help doctors in making decisions about treatment and monitoring of pancreatic cysts. The PanCystPro test measures glucose, carcinoembryonic antigen (CEA), and gastricsin biomarkers on fluid obtained from a pancreatic cyst. The test reports if the cyst fluid should be considered \"Non-mucinous\" or \"Mucinous\". Mucinous pancreatic cysts are more likely to progress to cancer while non-mucinous cysts seldom progress to cancer.",[78],"Pancreatic Cystic Lesions","2026-03-12",{"date":81,"type":82},"2026-03-16","ACTUAL",{"date":84,"type":82},"2026-02-17",{"date":86,"type":73},"2027-06-30",{"name":5,"class":6},3]